A carregar...
Amatuximab and novel agents targeting mesothelin for solid tumors
Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5687483/ https://ncbi.nlm.nih.gov/pubmed/29184420 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S145105 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|